101767-28-6

Basic information

• Product Name: 2-METHYL-THIAZOLE-4-CARBOXYLIC ACID HYDRAZIDE
• Synonyms: BUTTPARK 48\08-63;2-METHYL-4-THIAZOLECARBOHYDRAZIDE;2-METHYLTHIAZOLE-4-CARBOHYDRAZIDE;2-METHYL-THIAZOLE-4-CARBOXYLIC ACID HYDRAZIDE;4-Thiazolecarboxylicacid,2-methyl-,hydrazide(9CI);2-methyl-1,3-thiazole-4-carbohydrazide;2-Methyl-1,3-thiazole-4-carboxylic acid hydrazide, 4-(Hydrazinocarbonyl)-2-methyl-1,3-thiazole;4-Thiazolecarboxylic acid, 2-Methyl-, hydrazide
• CAS NO: 101767-28-6
• Molecular Formula: C₅H₇N₃OS
• Molecular Weight: 157.19
• Product Categories: AMIDE
• Mol File: 101767-28-6.mol

Chemical Properties

• Melting Point: 126-129
• Appearance: /
• Density: 1.355
• Refractive Index: 1.607
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 11.12±0.10(Predicted)
• CAS DataBase Reference: 2-METHYL-THIAZOLE-4-CARBOXYLIC ACID HYDRAZIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-METHYL-THIAZOLE-4-CARBOXYLIC ACID HYDRAZIDE(101767-28-6)
• EPA Substance Registry System: 2-METHYL-THIAZOLE-4-CARBOXYLIC ACID HYDRAZIDE(101767-28-6)

Safety Data

• Hazard Codes: Xi
• Statements: 20/21/22
• Safety Statements: 22-36/37/39
• Hazardous Substances Data: 101767-28-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Methyl-thiazole-4-carboxylic acid hydrazide is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of drugs with antimicrobial and antifungal properties. Its incorporation in drug formulations aids in the treatment of various diseases caused by microbial infections.
Used in Organic Chemistry:
In the realm of organic chemistry, 2-Methyl-thiazole-4-carboxylic acid hydrazide serves as a valuable precursor in the synthesis of other organic compounds. Its unique structure allows for further chemical reactions, facilitating the creation of a wide array of specialized organic molecules for various applications.
Used in Antimicrobial Applications:
2-Methyl-thiazole-4-carboxylic acid hydrazide is utilized as an antimicrobial agent, particularly effective against a range of bacteria and fungi. Its presence in antimicrobial products helps combat infections and promote overall health by limiting the growth of harmful microorganisms.
Used in Antifungal Applications:
Similarly, this compound is applied as an antifungal agent, targeting fungal infections. It is integrated into antifungal treatments to prevent and treat conditions caused by fungal overgrowth, thus supporting the maintenance of a healthy microbiome.

InChI:InChI=1/C5H7N3OS/c1-3-7-4(2-10-3)5(9)8-6/h2H,6H2,1H3,(H,8,9)

Upstream product

• 6436-59-5 ethyl 2-methylthiazole-4-carboxylate 

Downstream Products

• 1429557-03-8 (3-(2-methylthiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(thiophen-2-yl)phenyl)methanone 
• 1429560-58-6 (S)-(8-methyl-3-(2-methylthiazol-4-yl)-5,6-dihydro-[1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(thiophen-2-yl)phenyl)methanone 
• 1429558-36-0 (S)-4-(7-(2,4-dimethoxybenzyl)-8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)-2-methylthiazole 
• 1429607-62-4 (R)-4-(7-(2,4-dimethoxybenzyl)-8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)-2-methylthiazole 
• 1429556-99-9 (R)-(8-methyl-3-(2-methylthiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(thiophen-2-yl)phenyl)methanone 

Relevant articles and documents

FLUOROALKYL-OXADIAZOLES AND USES THEREOF

Provided herein are compounds identified as inhibitors of HDAC6 activity that can be used to treat various diseases and disorders.

Discovery and Optimization of Novel Antagonists to the Human Neurokinin-3 Receptor for the Treatment of Sex-Hormone Disorders (Part I)

Neurokinin-3 receptor (NK3R) has recently emerged as important in modulating the tonic pulsatile gonadotropin-releasing hormone (GnRH) release. We therefore decided to explore NK3R antagonists as therapeutics for sex-hormone disorders that can potentially benefit from lowering GnRH pulsatility with consequent diminished levels of plasma luteinizing hormone (LH) and correspondingly attenuated levels of circulating androgens and estrogens. The discovery and lead optimization of a novel N-acyl-triazolopiperazine NK3R antagonist chemotype achieved through bioisosteric lead change from the high-throughput screening (HTS) hit is described. A concomitant improvement in the antagonist bioactivity and ligand lipophilic efficiency (LLE) parameter were the principal guidelines in the lead optimization efforts. Examples of advanced lead analogues to demonstrate the amenability of this chemotype to achieving a suitable pharmacokinetic (PK) profile are provided as well as pharmacokinetic-pharmacodynamic (PKPD) correlations to analyze the trends observed for LH inhibition in castrated rats and monkeys that served as preliminary in vivo efficacy models. (Chemical Presented).

NOVEL CHIRAL N-ACYL-5,6,7,(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS AND CHIRAL SYNTHESIS THEREOF

The present invention relates to novel compounds of Formula I and their use in therapeutic treatments. The invention further relates to a novel chiral synthesis of 5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines using N-sp3 protective groups. The invention also provides intermediates for use in the synthesis of compounds of Formula I.